Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Psyence (PSYG) looks to expand capital market opportunities in the UK and Europe
  • Psyence is a global company with operations in Canada, the UK, Jamaica, South Africa and Lesotho, and a presence in the United States and Australia
  • It has a worldwide investor base, including shareholders in the UK and Europe, and is initiating a clinical trial in the UK
  • Psyence is a life science biotechnology company listed on the Canadian Securities Exchange and and quoted on the OTCQB
  • It has a the name “Psyence” because it combines the words psychedelic and science
  • Psyence Group Inc. (PSYG) is in the grey, trading at C$0.16 at 12:42 pm EST

Psyence Group Inc. (PSYG) is exploring capital market opportunities to access a broader pool of United Kingdom and European investors.

This includes a potential dual listing in the UK.

This is part of Psyence’s strategy to monitor and review its position within global capital markets with the view of maximizing returns for investors and increasing liquidity as well as supporting the company’s growth and value generation.

Psyence is a global company with operations in Canada, the UK, Jamaica, South Africa and Lesotho, and a presence in the United States and Australia.

It has a worldwide investor base, including shareholders in the UK and Europe, and is initiating a clinical trial in the UK using its natural psilocybin in the field of palliative care with oncology patients.

Psyence is a life science biotechnology company listed on the CSE and quoted on the OTCQB, with a focus on natural psychedelics.

Psyence works with natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care.

It has the name “Psyence” because it combines the words psychedelic and science
to affirm its commitment to producing psychedelic medicines developed through evidence-based research.

Informed by nature and guided by science, Psyence has built and operated one of the first federally licensed commercial psilocybin mushroom cultivation and production facilities in Lesotho, Southern Africa.

Its team brings international experience in both business and science and includes experts in mycology, neurology, palliative care, and drug development and it continues to develop advanced natural psilocybin products for clinical research and development.

Psyence Group Inc. (PSYG) is in the grey, trading at C$0.16 at 12:42 pm EST.

More From The Market Herald

" BlackBerry (TSX:BB) launches Google Chrome Enterprise Management

BlackBerry (BB) has launched Chrome Enterprise Management under its UEM service.
FansUnite - CEO, Scott Burton.

" FansUnite (CSE:FANS) reports Q1 2022 financial results

FansUnite (FANS) has filed its interim financial statements for the three months ended March 31, 2022.
Converge Technology Corp - CEO, Shaun Maine

" Converge Technology (TSX:CTS) announces licensing agreement with IBM

Converge Technology (CTS) announced a licensing agreement with IBM to extend its cloud capabilities with Converge Enterprise Cloud on IBM Power for Google
Infinity Stone Ventures - CEO, Zayn Kalyan.

" Infinity Stone (CSE:GEMS) upgrades graphite at Rockstone Graphite Property

Infinity Stone Ventures (GEMS) has successfully upgraded a graphite sample from its Rockstone Graphite Property to 96.1 per cent Cg (graphitic carbon).